These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36645543)

  • 1. Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources.
    Youn B; Proud CM; Wang N; Hou Q; Viscidi E; Eaton S; Paradis AD; Neville BA; Johnson NB
    Adv Ther; 2023 Mar; 40(3):1129-1140. PubMed ID: 36645543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
    Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
    Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
    MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
    CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study.
    Elman L; Youn B; Proud CM; Frey MR; Ajroud-Driss S; McCormick ME; Michelson D; Cartwright MS; Heiman-Patterson T; Choi JM; Chandak A; Khachatryan A; Martinez M; Paradis AD
    J Neuromuscul Dis; 2022; 9(5):655-660. PubMed ID: 36031906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 8. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
    Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims.
    Zhu C; Zaidman C; Youn B; Paradis AD; Raynaud S; Neville BA; Johnson NB
    J Comp Eff Res; 2024 Jul; 13(7):e230187. PubMed ID: 38963060
    [No Abstract]   [Full Text] [Related]  

  • 11. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
    Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
    Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study.
    Viscidi E; Wang N; Juneja M; Bhan I; Prada C; James D; Lallier S; Makepeace C; Laird K; Eaton S; Dilley A; Hall S
    Orphanet J Rare Dis; 2021 May; 16(1):207. PubMed ID: 33962637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.